MENLO PARK, Calif. — August 7, 2025 — Leads & Copy — PacBio (NASDAQ: PACB) announced its financial results for the second quarter of 2025, which ended June 30. The company reported a revenue of $39.8 million, compared to $36.0 million in Q2 2024. Instrument revenue was $14.2 million, while consumable revenue reached $18.9 million. Service and other revenue amounted to $6.7 million.
The company highlighted several key updates since its last earnings release, including the publication of the Platinum Pedigree benchmark in Nature Methods and joining the 1000 Genomes Long Read Project. Additionally, PacBio expanded its distribution in China through an agreement with Haorui Gene.
“PacBio returned to both sequential and year-over-year revenue growth in the second quarter, while also continuing to reduce operating expenses and cash burn,” said Christian Henry, President and Chief Executive Officer.
The company’s management will host a conference call today at 5:00 p.m. Eastern Time to discuss the results.
Todd Friedman, Investors: ir@pacb.com
Media: pr@pacb.com
Source: PacBio
